Historique
Article de Périodique
Adverse events of recreational cannabis use during pregnancy reported to the French Addictovigilance Network between 2011 and 2020 (2022)
Auteur(s) :
BOUQUET, E. ;
EIDEN, C. ;
FAUCONNEAU, B. ;
PION, C. ;
French Addictovigilance Network (FAN) ;
PAIN, S. ;
PERAULT-POCHAT, M. C.
Année
2022
Page(s) :
art. 16509
Langue(s) :
Anglais
Refs biblio. :
38
Domaine :
Drogues illicites / Illicit drugs
Discipline :
EPI (Epidémiologie / Epidemiology)
Thésaurus géographique
FRANCE
Thésaurus mots-clés
CANNABIS
;
USAGE RECREATIF
;
GROSSESSE
;
ADDICTOVIGILANCE
;
EVOLUTION
;
SEXE FEMININ
;
MALFORMATION
;
FOETUS
;
NOUVEAU-NE
;
TYPE D'USAGE
;
EFFET SECONDAIRE
Résumé :
Cannabis is the main illicit psychoactive substance used by pregnant women in France. The aim of the present national survey was to describe adverse events (AEs) of recreational cannabis use during pregnancy reported to the French Addictovigilance Network (FAN). Spontaneous reports (SRs) of AEs related to recreational cannabis use during pregnancy were collected by the FAN between 01/01/2011 and 31/01/2021 (excluding cannabidiol and synthetic cannabinoids). Over the study period, 160 SRs involved cannabis use alone or in association with tobacco (59% of all SRs) which increased. Among the 175 maternal AEs, the most commons were psychiatric AEs experienced by 96 (64.9%) women, in particular cannabis use disorders (n = 89, 60.1%), dependence (n = 54, 36.5%) and abuse (n = 21, 14.2%). Among the 57 fetal AEs, the most common were heart rhythm disorders that affected 25 (16.9%) fetuses and intrauterine growth restriction (IUGR) (n = 20, 13.5%). Among the 140 neonatal AEs, the most common were IUGR experienced by 39 (26.3%) newborns and prematurity (n = 32, 21.6%). Twelve cases of congenital malformations were observed and 4 intrauterine/neonatal deaths. Furthermore, some of these AEs (n = 13) were unexpected. Cannabis use during pregnancy has problematic consequences for both mothers and infants who need close monitoring.
Affiliation :
Department of Clinical Pharmacology, Addictovigilance Center, Poitiers University Hospital, Poitiers, France
Experimental and Clinical Neurosciences Laboratory, INSERM U-1084, University of Poitiers, Poitiers, France
Addictovigilance Center, Montpellier University Hospital, Montpellier, France
French National Agency for Medicines and Health Products Safety (ANSM), Saint-Denis, France
Experimental and Clinical Neurosciences Laboratory, INSERM U-1084, University of Poitiers, Poitiers, France
Addictovigilance Center, Montpellier University Hospital, Montpellier, France
French National Agency for Medicines and Health Products Safety (ANSM), Saint-Denis, France